CAMBRIDGE, Mass., Sept. 26, 2016 /PRNewswire/ -- Amgen
(NASDAQ: AMGN) today announced that the nomination process to
submit proposals to receive an Amgen-sponsored LabCentral Golden
Ticket is open for interested life-sciences and biotech startup
companies in Massachusetts.
LabCentral is an innovative, shared laboratory space designed as a
launch pad for premier high-impact life-sciences and biotech
startups. As one of LabCentral's platinum sponsors, Amgen can
nominate up to two early-stage companies each year to take up
residence in LabCentral's Kendall
Square facilities in Cambridge,
Mass.
"Amgen is pleased to launch the process to identify Golden
Ticket winners," said Aine Hanly,
vice president of Process Development and site head at Amgen
Massachusetts. "It's exciting to learn about the breadth of
innovative research that is taking place within startup companies
throughout Massachusetts. Amgen is committed to rewarding
innovators who are advancing potentially game-changing, early-stage
research that have the ability to impact patients' lives."
"We know there are many more life-science visionaries with great
technology and terrific science, and we're thrilled that Amgen
continues to make such a strong commitment to promoting and
supporting our Golden Ticket program," said LabCentral Co-Founder
and President Johannes Fruehauf,
M.D., Ph.D. "These contests help get the word out, ensuring that
there continues to be a broad pool of applicants with the highest
potential. Further, since Amgen helps defray the cost of membership
at LabCentral – without asking for any conditions – it may give
winners a chance to get into LabCentral earlier than they may have
otherwise. Once there, everyone thrives to the benefit of the
entire life-sciences community."
The 2016 Golden Ticket nomination process opened on Sept. 6, 2016. During this round, Amgen will
sponsor one promising life-sciences and biotech startup company to
reside in LabCentral's facilities. The Golden Ticket
represents one year of bench space for one scientist. Interested
companies should send non-confidential company presentation for
consideration to GoldenTicket@amgen.com by Oct. 30, 2016. Amgen will notify on Dec. 10, 2016.
Since the collaboration launched in 2014, Amgen has awarded a
Golden Ticket to Novopyxis, Cocoon Biotech and Platelet
Biogenesis.
About Amgen
Amgen is committed to unlocking
the potential of biology for patients suffering from serious
illnesses by discovering, developing, manufacturing and delivering
innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease
and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and
leverages its expertise to strive for solutions that improve health
outcomes and dramatically improve people's lives. A biotechnology
pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us
on www.twitter.com/amgen.
About LabCentral (www.labcentral.org; twitter
@labcentral)
A 28,000 square-foot facility in the heart of
the Kendall Square, Cambridge, biotech innovation hub,
LabCentral is a first-of-its-kind shared laboratory space designed
as a launchpad for high-potential life-sciences and biotech
startups. It offers fully permitted laboratory and office space for
early-stage companies comprising approximately 125 scientists and
entrepreneurs. LabCentral provides first-class facility and
administrative support, skilled laboratory personnel, a
domain-relevant expert speaker series ‒ as well as the other
critical services and support that startups need to begin
laboratory operations on day one. A private, nonprofit institution,
LabCentral was funded in part by a $5 million grant from
the Massachusetts Life Sciences Center, with support from its
real-estate partner, MIT. Founding sponsors include
Triumvirate Environmental and Johnson & Johnson Innovation.
Contact:
Amgen, Massachusetts
Jennifer Bianco, (401) 392-8815
biancoj@amgen.com
LabCentral, Massachusetts
Caroline Grossman, (781)
771-5579
cgrossman@labcentral.org
Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-opens-nomination-process-for-labcentral-residency-300334180.html
SOURCE Amgen